All News Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Market Closed - Nasdaq Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
5.71 ^USD	-4.83%		+11.52%	-26.70%

05/06	Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call
14/05	Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression	13/06	BU
Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call	05/06
Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update	14/05	BU
Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC	14/05	CI
Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Syros to Participate in Upcoming Investor Conferences	07/05	BU
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024	07/05	BU
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	10/04	MT
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09/04	MT
Syros Gets FDA Fast-Track Designation for Tamibarotene	09/04	DJ
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04	BU
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04	CI
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04	AQ
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04	BU
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	29/03	DJ
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	28/03	DJ
Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024	27/03
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	27/03	MT
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27/03	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

All News

Filters